Sanofi presented 39 abstracts on its approved and pipeline medicines at the 2024 European Academy of Dermatology and Venereology (EADV) medical meeting in Amsterdam, the Netherlands. The presentations, which ran from September 25-28, included data on Dupixent (dupilumab) and pipeline molecules like amlitelimab and rilzabrutinib, addressing conditions such as atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU). These findings highlight Sanofi's commitment to advancing treatments for immune-mediated skin diseases.
Dupixent Data Highlights
Twenty-one abstracts focused on Dupixent, a drug developed in partnership with Regeneron, demonstrating its impact on IL-4 and IL-13 pathways across AD, PN, and CSU. Notably, new data indicated the potential for clinical remission in children as young as six years old with moderate-to-severe AD. An oral presentation showcased real-world safety data for Dupixent in adults and adolescents with moderate-to-severe AD from a multinational prospective observational study.
In prurigo nodularis, new analyses from the PRIME and PRIME2 pivotal clinical studies revealed rapid improvements in disease activity, itch, and skin clearance as early as two weeks after treatment initiation. The safety results were consistent with the known safety profile of Dupixent in its approved dermatological indications.
Immunology Pipeline Updates
Sanofi's immunology pipeline featured 15 abstracts, including presentations on amlitelimab, an OX40-ligand monoclonal antibody, and rilzabrutinib, a novel oral BTK inhibitor. Amlitelimab showed promising safety and efficacy results in moderate-to-severe AD, with a pharmacokinetic model suggesting the potential for quarterly dosing. Rilzabrutinib demonstrated positive effects on AD and CSU symptoms in poster presentations.
Amlitelimab
Six presentations covered amlitelimab in moderate-to-severe AD, including 68-week safety results. An in vitro analysis indicated that amlitelimab's anti-OX40L mechanism does not deplete T cells, suggesting a favorable safety profile.
Rilzabrutinib
Rilzabrutinib's impact on itch in adults with moderate-to-severe AD was presented in a poster. Additionally, three poster presentations highlighted rilzabrutinib's effects on itch, hives, and urticaria in adults with moderate-to-severe CSU.
Additional Research Areas
The conference also included presentations on hidradenitis suppurativa and alopecia areata, focusing on disease awareness and patient experiences. Three poster presentations addressed the impact of hidradenitis suppurativa symptoms on patients, emphasizing the need for increased disease awareness and effective treatment options. A poster presentation explored conceptual models and clinical outcome measures in alopecia areata based on patient experiences.
Expert Commentary
"Our data at EADV highlight the breadth of our diverse and novel approach across inflammatory dermatologic conditions, including AD, PN and CSU," said Dietmar Berger, M.D., Ph.D., Chief Medical Officer, Global Head of Development at Sanofi. "Dupixent data demonstrates the potential benefit of important treatment goals such as clinical remission and the speed and durability of efficacy. Additionally, we are excited to share new data from our pipeline, including results for amlitelimab showing the potential to provide durable efficacy that may enable a quarterly dosing interval, with favorable safety profile."
